NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based personalized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immune-oncology, ischemic repair and immunomodulation) with a lead, late-stage (Phase 3, 2 and 2, respectively) clinical program for each. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development.
Our mission is to transform the future of medicine with innovative cell based therapies while providing development and manufacturing services that drive the industry forward.
At NeoStem, we are committed to showing the world the path to better medicine. Our goal is to reduce a lifetime dependency on pills to a single dose of cells and help society reduce the burden of an unsustainable healthcare system. Our vision is a world where chronic disease is a problem of the past and patients have the freedom to enjoy a healthier span of life. We truly believe that cell therapies will be better medicine.